An Overview Of Pembrolizumab for High-Risk BCG Unresponsive NMIBC

EP: 1.Assessing Risk in NMIBC: A Foundation for Therapy

EP: 2.From Papillary to CIS: Tailoring NMIBC Treatment

EP: 3.Defining and Managing BCG-Unresponsive NMIBC

EP: 4.NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up

EP: 5.FDA-Approved Options for High-Risk BCG-Unresponsive NMIBC

Now Viewing

EP: 6.An Overview Of Pembrolizumab for High-Risk BCG Unresponsive NMIBC

EP: 7.An Overview of Nogapendekin Alfa Inbakicept for High-Risk, BCG-Unresponsive NMIBC

EP: 8.Real-World Outcomes With Nadofaragene in BCG-Unresponsive NMIBC

EP: 9.Exploring Nadofaragene Firadenovec: Ongoing Trials and Study Designs

EP: 10.Topline Results From Recent NMIBC Trials

EP: 11.Overcoming Challenges in Accessing New Therapies for NMIBC

EP: 12.Navigating Access Barriers: Resources to Support New Treatment Access

EP: 13.Reflecting on NMIBC Progress: Highlights From AUA 2025 and What’s Ahead

Physician Summary:

Pembrolizumab (Keytruda)

• Mechanism of Action: Pembrolizumab is a PD-1 inhibitor that works by blocking the interaction between the PD-1 receptor on T cells and its ligands (PD-L1/PD-L2) on tumor cells. This enhances the immune system’s ability to recognize and attack cancer cells, particularly effective in treating carcinoma in situ and in cases with or without papillary tumors in BCG-unresponsive NMIBC.
• Administration: Unlike intravesical treatments, pembrolizumab is administered intravenously, typically every 3 weeks. This systemic approach allows it to target tumors throughout the body but requires careful monitoring for potential immune-related adverse effects.

Pembrolizumab offers a novel approach to managing high-risk, BCG-unresponsive NMIBC by harnessing the power of immunotherapy. Its ability to selectively block immune checkpoint signaling makes it effective in cases where traditional therapies fail.